Hims & Hers Health

• Annual subscription discount
• Personalized dosing tier

What Hims & Hers Health actually is

Hims & Hers Health is the largest publicly-traded telehealth company in the US selling compounded GLP-1 products under the 503A pharmacy pathway. The company operates a hybrid model: it owns or affiliates with dispensing pharmacies in its network, runs the consumer-facing telehealth intake and subscription billing platform, and contracts with prescribers for the medical-consult step.

This is a structurally different audit subject than the distributor brands (Trillium, Fifty410) covered earlier in our v0 cohort. Hims is not a marketplace routing prescriptions to third-party compounders. It is closer to an end-to-end operator: telehealth + prescriber + owned or affiliated dispensing pharmacy + subscription billing under one publicly-traded company. The vertical integration is the source of both the platform's operational maturity and its concentrated regulatory exposure.

Why the regulatory frame is the audit's center of mass

The single most important fact about Hims as an audit subject is that the FDA's shortage-status discretion for both semaglutide and tirzepatide ended in 2025. Compounded GLP-1s prepared under section 503A of the Federal Food, Drug, and Cosmetic Act are only legal in narrow circumstances. The "shortage" exception (under which most telehealth compounders entered the market in 2023-2024) closed when the FDA determined the drugs were no longer in shortage. After that closure, the legal pathway for 503A compounding of these molecules narrowed to the "clinical-need personalization" exception - the pharmacy compounds because a specific patient cannot use the commercially-available drug for a specific clinical reason.

Hims's continued sale of compounded semaglutide and tirzepatide after the shortage closure has been framed by the company as falling under the personalization pathway. The FDA's public position is that personalization claims must be tied to documented clinical need, not used as a marketing pathway to preserve the shortage-era business model. The tension between those two readings is the live regulatory question facing Hims specifically and the entire post-shortage telehealth-compounder cohort more generally. We covered the regulatory backdrop in detail in 503A and the PCAC: how compounding restrictions closed the legal GLP-1 market and compounded semaglutide in 2026: where the legal channel actually stands.

The Novo Nordisk partnership and its public termination

In mid-2025 Hims and Novo Nordisk announced a partnership under which Hims would sell branded Wegovy to its members at a discounted price. The partnership was widely interpreted as Novo's attempt to convert the telehealth-compounder customer base into branded-product customers after the shortage closed.

Within weeks of the announcement, Novo Nordisk publicly terminated the partnership, citing concerns that Hims was continuing to promote and sell compounded versions of semaglutide alongside the branded product and that Hims's marketing did not adequately distinguish the FDA-approved branded drug from its compounded variants. The termination was unusually public and unusually fast for a brand-manufacturer / telehealth-platform deal in any therapeutic area.

For an audit subject this matters in two ways. First, the public dispute is part of the verifiable record - this is not a rumor or a short-seller claim, it is a documented termination between two publicly-traded counterparties. Second, the termination's stated rationale (continued compounded sales alongside branded sales) goes directly to the regulatory question the audit rubric weights most heavily.

Where Hims scores

The composite rating reflects a structurally different shape from the distributor brands in our cohort. Hims scores higher on platform maturity, state licensure breadth, and price transparency. It scores lower on the dimensions where the post-shortage regulatory question concentrates: FDA-history risk, sourcing transparency, and buyer protection.

The 5.0 FDA-history score does not reflect a warning letter or 483 of the kind that drags Trillium's record on the Hallandale partner. No such direct action against Hims's affiliated pharmacies has been surfaced in our public-record pass. The score instead reflects the elevated regulatory pressure on the personalization-pathway business model as a whole, which the FDA has publicly flagged. Buyers should weight that dimension differently depending on whether they prioritize documented past actions against this specific pharmacy network (against which the score would be higher) or the prospective regulatory pressure on the entire compounded-GLP-1 channel (which is what the score actually weights).

The 5.0 sourcing score reflects the absence of a publicly-disclosed API-supplier dossier at the upstream-manufacturer level. Pharmacies that publish their API sourcing earn a higher score on this dimension. Hims's larger scale makes this gap more material than it would be for a small distributor.

The 4.5 buyer-protection score reflects the recurring cancellation and refill-friction grievances surfaced on Trustpilot and r/ tirzepatidecompound, weighted against the absence of a published formal grievance procedure outside the standard telehealth-platform support channel.

What buyers consistently report

Across roughly 12,000 Trustpilot reviews, Hims carries a rating in the 3.7-3.9 band. That is materially below the smaller compounders in our cohort (Trillium 4.5, Fifty410 4.7). The volume is the largest in the category, which makes the reading more statistically reliable than the distributors' smaller samples - but the rating gap is real and consistent.

The recurring positive themes are platform reliability, prescription delivery cadence, and the visibility of a publicly-traded operator that is unlikely to vanish overnight. The recurring negative themes are subscription cancellation friction, mixed product quality at the fill level, billing surprises on auto-renewal, and a perception that customer-support escalation is harder than at smaller compounders. The May 2026 monthly survey on r/Tirzepatidecompound did not place Hims in tier-1 or tier-2 cohorts despite Hims's larger absolute customer base.

The structural caveat on buyer-experience signal is the same as for Trillium. Buyer satisfaction measures the platform's UX, not the compounding pharmacy's sterility practice. A 3.8 Trustpilot score and a clean (or unclean) FDA record are measuring different things.

What's missing from public records

This audit is the public-data tier. To upgrade Hims to a full audit tier we would need:

• A first-hand consult and fill placed by the vialaudit desk, with the affiliated dispensing pharmacy identified pre-purchase if available, or documented as undisclosed if not
• The named-prescriber identity and NPI number tied to the fill, with state-medical-board cross-checks for the state the fill ships to
• Per-state non-resident pharmacy license verification for each affiliated dispensing facility, pulled directly from each state's Board of Pharmacy database
• The Hims written refund and cancellation policy as published, archived against any future quiet revisions
• A third-party lab test on the actual fill, against label claim for identity and purity (HPLC + mass spec)
• A snapshot of any pending or recent FDA correspondence with the affiliated dispensing pharmacies. SEC filings and earnings calls may reference FDA correspondence that is not separately published in the FDA inspection database

We have not done that work yet. This profile reflects what is verifiable from public records as of the last-audited date.

Editorial note - the largest is the most exposed

This profile is the second editorial spine of the v0 compounding- pharmacy vertical, after the Trillium "buyer-survey winner is not the audit winner" finding. The Hims version of the divergence is different: the largest operator in the category is also the most concentrated regulatory exposure. The platform is mature, the pricing is competitive, and the audited-financials disclosure regime around a public company is a transparency advantage smaller pharmacies do not have. None of those properties resolve the personalization-pathway question that the entire post-shortage compounded-GLP-1 channel sits on top of.

A buyer optimizing for platform reliability, brand recognition, and the implicit safety net of a publicly-traded operator has reasons to choose Hims that this audit does not contradict. A buyer optimizing for the lowest prospective regulatory risk on the actual fill should read the FDA's public statements on the personalization pathway carefully before committing to any post-shortage 503A compounded GLP-1, Hims included.

See /methodology/compounding for the rubric weights that produce this score and the conflict-of-interest constraints that govern this desk.

• Hims & Hers Health homepage↗ — vendor
• Hims & Hers Health - investor relations & SEC filings↗ — company / SEC
• FDA - Compounding under section 503A of the Federal Food, Drug, and Cosmetic Act↗ — FDA
• FDA - Compounding inspections, recalls, and other actions↗ — FDA
• Hims & Hers Health - Trustpilot profile↗ — Trustpilot
• r/tirzepatidecompound May 2026 telehealth & pharmacy survey↗ — Reddit community survey
• vialaudit - Compounded semaglutide in 2026 status read↗ — vialaudit
• vialaudit - 503A and the PCAC GLP-1 compounding article↗ — vialaudit